GlassScriptPhysician profile
Charmaine Ansari
NPI 1972613297
$2,576.10
in general payments reported to CMS, 2019-2025
26 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $86.09 · 2022: $241 · 2023: $561 · 2024: $688 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,569.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $291.55 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $241.47 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.54 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $232.85 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $169.07 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $161.57 | 2019-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $156.36 | 2019-2022 | |
| Madrigal Pharmaceuticals | $147.88 | 2025 | Rezdiffra |
| Lilly USA, LLC | $141.99 | 2019-2025 | Mounjaro, Zepbound |
| Medtronic, INC. | $137.78 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Astrazeneca Pharmaceuticals LP | $114.37 | 2019-2025 | Lokelma, Breztri, Fasenra |
| Janssen Pharmaceuticals, INC | $100.18 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $82.83 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $66.25 | 2024 | Ingrezza |
| Merck Sharp & Dohme LLC | $58.14 | 2022-2024 | Verquvo, Belsomra, Gardasil |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $37.79 | 2020 | |
| Aimmune Therapeutics, INC. | $29.56 | 2024-2025 | Zenpep |
| Abbvie INC. | $28.07 | 2024 | |
| Dexcom, INC. | $26.53 | 2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $24.70 | 2022 | |
| Abbott Laboratories | $20.86 | 2022 | |
| Ironwood Pharmaceuticals, INC | $17.56 | 2023 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.67 | 2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $13.95 | 2023 | |
| Sanofi-Aventis U.S. LLC | $13.44 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charmaine Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.